| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/JNR.22825 |
| P8608 | Fatcat ID | release_dvgeyxpf5ved5acibx7o5w5isq |
| P698 | PubMed publication ID | 22253213 |
| P2093 | author name string | Jens Schmidt | |
| Josbert M Metselaar | |||
| Lars Klinge | |||
| Jana Zschüntzsch | |||
| Gregor Makosch | |||
| David Liebetanz | |||
| Charlotte Weller | |||
| Florian Klinker | |||
| P2860 | cites work | Dopamine D3 receptor specifically modulates motor and sensory symptoms in iron-deficient mice. | Q48323251 |
| A highly sensitive automated complex running wheel test to detect latent motor deficits in the mouse MPTP model of Parkinson's disease | Q48411048 | ||
| Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. | Q51761621 | ||
| Small-caliber skeletal muscle fibers do not suffer necrosis in mdx mouse dystrophy. | Q54379136 | ||
| Glucocorticoids and immunosuppressants do not change the prevalence of necrosis and regeneration in mdx skeletal muscles | Q57043608 | ||
| Weekly oral prednisolone improves survival and strength in malemdx mice | Q57270368 | ||
| Glucocorticoid corticosteroids for Duchenne muscular dystrophy | Q24242199 | ||
| Dystrophin: the protein product of the Duchenne muscular dystrophy locus | Q29618077 | ||
| Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy | Q29619282 | ||
| Effects of prednisolone on skeletal muscle contractility in mdx mice | Q33887318 | ||
| Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures | Q33975979 | ||
| FOXO3a mediates signaling crosstalk that coordinates ubiquitin and atrogin-1/MAFbx expression during glucocorticoid-induced skeletal muscle atrophy | Q34017130 | ||
| Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models. | Q34699458 | ||
| Liposomes for intravenous drug targeting: design and applications | Q34948531 | ||
| Interleukin-15 administration improves diaphragm muscle pathology and function in dystrophic mdx mice | Q35083822 | ||
| Targeting the immune system to improve ventilatory function in muscular dystrophy | Q35621224 | ||
| Adaptive and nonadaptive responses to voluntary wheel running by mdx mice | Q36083617 | ||
| Pathophysiology of duchenne muscular dystrophy: current hypotheses | Q36680425 | ||
| Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy | Q36841572 | ||
| Endurance capacity in maturing mdx mice is markedly enhanced by combined voluntary wheel running and green tea extract | Q36877501 | ||
| The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. | Q37120241 | ||
| Mechanisms of glucocorticoid-induced myopathy | Q37121299 | ||
| Developing standard procedures for murine and canine efficacy studies of DMD therapeutics: report of two expert workshops on "Pre-clinical testing for Duchenne dystrophy": Washington DC, October 27th-28th 2007 and Zürich, June 30th-July 1st 2008. | Q37396962 | ||
| Role of cytokines and chemokines in idiopathic inflammatory myopathies. | Q37591130 | ||
| Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management | Q37640907 | ||
| Signaling pathways perturbing muscle mass | Q37732100 | ||
| The role and regulation of MAFbx/atrogin-1 and MuRF1 in skeletal muscle atrophy. | Q37827379 | ||
| Liposomal glucocorticosteroids in treatment of chronic autoimmune demyelination: long-term protective effects and enhanced efficacy of methylprednisolone formulations | Q40105599 | ||
| Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis | Q40581554 | ||
| Inhibiting TGF-β activity improves respiratory function in mdx mice | Q42732727 | ||
| Impact of prednisone on TGF-beta1 and collagen in diaphragm muscle from mdx mice | Q43608185 | ||
| Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. | Q44255035 | ||
| Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes | Q44504463 | ||
| Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis | Q44992354 | ||
| Prednisolone decreases cellular adhesion molecules required for inflammatory cell infiltration in dystrophin-deficient skeletal muscle | Q45036102 | ||
| Localization and early time course of TGF-beta 1 mRNA expression in dystrophic muscle | Q45076412 | ||
| Strength and corticosteroid responsiveness of mdx mice is unchanged by RAG2 gene knockout | Q46280029 | ||
| Reduced muscle necrosis and long-term benefits in dystrophic mdx mice after cV1q (blockade of TNF) treatment | Q46799394 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 1067-1077 | |
| P577 | publication date | 2012-01-18 | |
| P1433 | published in | Journal of Neuroscience Research | Q6295654 |
| P1476 | title | Motor performance of young dystrophic mdx mice treated with long-circulating prednisolone liposomes | |
| P478 | volume | 90 |
| Q90045029 | Glycine administration attenuates progression of dystrophic pathology in prednisolone-treated dystrophin/utrophin null mice |
| Q86421528 | Human immunoglobulin G for experimental treatment of Duchenne muscular dystrophy |
| Q41527279 | Treatment with human immunoglobulin G improves the early disease course in a mouse model of Duchenne muscular dystrophy |
Search more.